Who Paid My Doc
Zinplava
Biological Infectious Disease
NDC 0006-3025-00
General payments
$1,270,071
Research payments
$2,795,644
Through program year 2025, $1,270,071 in general payments and $2,795,644 in research payments were reported against Zinplava (Infectious Disease).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
13 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $257 | 9 |
| 2024 | General | $8,772 | 456 |
| 2024 | Research | $243,876 | 5 |
| 2023 | General | $27,616 | 1,133 |
| 2023 | Research | $281,514 | 9 |
| 2022 | General | $220,101 | 11,743 |
| 2022 | Research | $436,924 | 38 |
| 2021 | General | $170,169 | 9,626 |
| 2021 | Research | $630,548 | 34 |
| 2020 | General | $95,036 | 3,827 |
| 2020 | Research | $242,353 | 92 |
| 2019 | General | $748,120 | 9,021 |
| 2019 | Research | $960,429 | 194 |
Breakdown
The top 5 of 9 recipients; each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
35,815 general · 372 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.